A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.

Abstract

Glioblastoma multiforme (GBM) is the most common and deadliest of malignant brain tumors in adults. Disease development is associated with dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway, resulting in increased proliferation; thus, CDK4/6 kinase inhibitors are promising candidates for GBM treatment. The recently developed CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are effective in subcutaneous glioma models, but their blood-brain barrier (BBB) permeability is poor, limiting drug delivery to the central nervous system. Here, we designed and synthesized a series of novel CDK4/6 inhibitors with favorable BBB permeability for the treatment of GBM. Compound 11 exhibited a favorable pharmacological profile and significant penetration of the BBB with the Kp value of 4.10 and the Kp,uu value of 0.23 in mice after an oral dose of 10 mg/kg. IC50 values for CDK4/cyclin D1 and CDK6/cyclin D3 were 3 nM and 1 nM, respectively. In vivo studies with an orthotopic xenograft mouse model of GBM showed that 11 had tumor growth inhibition values ranging from 62% to 99% for doses ranging from 3.125 to 50 mg/kg, and no significant body weight loss was observed. The increase in life span based on the median survival time of vehicle-treated animals in mice administered a dose of 50 mg/kg was significant at 162% (p < 0.0001). These results suggest that compound 11 is a promising candidate for further investigation as an effective drug for the treatment of GBM.

• Authors: Lei Yin, Heng Li, Wenjian Liu, Zhenglin Yao, Zhenzhen Cheng, Huabei Zhang, Hui Zou
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 144 Pg. 1-28 (Jan 20 2018) ISSN: 1768-3254 [Electronic] France
• PMID: 29247857 (Publication Type: Journal Article)
• Copyright: Copyright © 2017. Published by Elsevier Masson SAS.

Chemical References

• Protein Kinase Inhibitors
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6

Topics

• Animals
• Blood-Brain Barrier (metabolism, pathology)
• Brain Neoplasms (drug therapy, metabolism, pathology)
• Cell Line, Tumor
• Cyclin-Dependent Kinase 4 (antagonists & inhibitors, metabolism)
• Cyclin-Dependent Kinase 6 (antagonists & inhibitors, metabolism)
• Dogs
• Drug Design
• Glioblastoma (drug therapy, metabolism, pathology)
• Humans
• Madin Darby Canine Kidney Cells
• Male
• Mice
• Protein Kinase Inhibitors (chemistry, pharmacokinetics, therapeutic use)